Clinical Trial Update: Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating prophylactic ranibizumab for exudative age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Leonard Feiner, MD, PhD | Conditions: Age-related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED